Research & Development

AMV564, a novel CD33xCD3 bispecific antibody is currently under investigation in a Phase 1 clinical study in patients with relapsed or refractory acute myeloid leukemia (AML). Amphivena plans to launch a Phase 1 clinical study in patients with myelodysplastic syndrome (MDS) in early 2018.

read more



We are committed and passionate about developing the best and most innovative therapies for cancer patients. We have forged world class alliances that combine the strengths, expertise and resources of our industry and academic collaborators.

read more

Healthy stock market


Amphivena Therapeutics, Inc., founded in July 2013, is a clinical stage company based in South San Francisco, California

read more

About Amphivena

Restoring the flow of life

Our mission is to eradicate blood cancers with a breakthrough therapy that harnesses the patient’s own immune system to destroy tumor cells and their precursors. Our aim is to restore the cellular balance needed for proper blood formation, function and circulation, restoring the flow of life to patients.

read more

Latest News

  1. Amphivena’s Human Proof-of-Concept Data for AMV564 in Relapsed/Refractory AML Updated at the European Hematology Association Annual Meeting

    July 1, 2019

  2. Amphivena Expands Executive Team

    March 5, 2019

error: Content is protected !!